Purple Biotech Ltd (KTOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Purple Biotech Ltd (KTOV) has a cash flow conversion efficiency ratio of -0.041x as of June 2020. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.32 Million ≈ $-6.22K USD) by net assets (ILA56.15 Million ≈ $150.52K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Purple Biotech Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Purple Biotech Ltd - Cash Flow Conversion Efficiency Trend (2013–2019)
This chart illustrates how Purple Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Purple Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech Ltd ranked by their cash flow conversion efficiency. See Purple Biotech Ltd cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MOVEBYBIKE EUROPE AB
F:6ZR
|
-7.892x |
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
-0.522x |
|
PURANIUM ENERGY LTD.
F:2DK
|
0.113x |
|
Zapp Electric Vehicles Group Limited Ordinary Shares
NASDAQ:ZAPP
|
0.000x |
|
Hennessy Capital Investment Corp. VII Rights
NASDAQ:HVIIR
|
N/A |
|
SECITS Holding AB (publ)
ST:SECI
|
0.666x |
|
Time Out Group plc
LSE:TMO
|
-0.052x |
|
iQ International AG
F:IQL
|
0.040x |
Annual Cash Flow Conversion Efficiency for Purple Biotech Ltd (2013–2019)
The table below shows the annual cash flow conversion efficiency of Purple Biotech Ltd from 2013 to 2019. View KTOV share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2019-12-31 | ILA10.86 Million ≈ $29.11K |
ILA-5.58 Million ≈ $-14.96K |
-0.514x | +33.31% |
| 2018-12-31 | ILA11.00 Million ≈ $29.50K |
ILA-8.48 Million ≈ $-22.73K |
-0.771x | +23.24% |
| 2017-12-31 | ILA8.59 Million ≈ $23.04K |
ILA-8.63 Million ≈ $-23.13K |
-1.004x | -114.60% |
| 2016-12-31 | ILA13.38 Million ≈ $35.88K |
ILA-6.26 Million ≈ $-16.79K |
-0.468x | -33.35% |
| 2015-12-31 | ILA9.43 Million ≈ $25.28K |
ILA-3.31 Million ≈ $-8.87K |
-0.351x | +93.40% |
| 2014-12-31 | ILA851.00K ≈ $2.28K |
ILA-4.53 Million ≈ $-12.13K |
-5.318x | -1082.67% |
| 2013-12-31 | ILA-946.00K ≈ $-2.54K |
ILA-512.00K ≈ $-1.37K |
0.541x | -- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more